Home / Actual products: Co / COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5microg...
COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5microg...
- ID
- 40872011000001104
- Virtual product
- Generic COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials
- Name
- COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials
- Abbreviated name
- COVID-19 Vacc VidPrevtyn (B.1.351) 0.5ml inj multidose vials
- Description
- COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi)
- Date of name applicability
- 10 Jan 2023
- Previous Name
- COVID-19 Vaccine Sanofi (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose emulsion for injection multidose vials
- Supplier
- Sanofi
- Licensed as
- Medicines - MHRA/EMA
- Previously licensed as
- None
- License change reason
- Licence Granted
- Date of change of licensing authority
- 10 Jan 2023
- EMA (European Medicines Agency) Monitoring
- 1
- Restrictions on availability
- Restricted Availability
- Licensed route
- Intramuscular